Skip to main content

Table 2 Quality assessment results of economic evaluation reporting using the CHEERS checklist

From: Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

Item (Item No) Number of studies met the recommendations Percentage (%) %Agreement†
Target population and subgroups (4) 59/59 100 98
Study perspective (6) 50/59 85 81
Comparators (7) 58/59 98 98
Time horizon (8) 54/59 92 98
Discount rate for costs and outcomes (9) †† 32/39 82 86
Measurement of effectiveness (Single study-based estimates) (11a)# 50/50 100 95
Measurement of effectiveness (Synthesis-based estimates) (11b) ## 9/9 100 95
Estimating resources and costs (Single study-based EE) (13a)* 9/9 100 95
Estimating resources and costs (Model-based EE) (13b)** 50/50 100 95
Study parameters (18) 50/59 85 84
Incremental costs and outcomes (19) 57/59 97 95
Characterizing uncertainty (Single study-based EE) (20a)* 2/9 22 98
Characterizing uncertainty (Model-based EE) (20b)** 50/50 100 100
Source of funding (23) 47/59 80 95
Conflicts of interest (24) 46/59 78 97
  1. EE: Economic evaluation
  2. † Percent agreement between two independent raters
  3. †† The denominator for the calculations is the studies that reported the discount rate for costs and/or outcomes were from a study period longer than one year, including 39 studies
  4. # The denominator for the calculations is a single study-based estimate of clinical effectiveness data, including 50 studies
  5. ## The denominator for the calculations is synthesis-based estimates of clinical effectiveness data, including 9 studies
  6. * The denominator for the calculations is a single study-based economic evaluation, including 9 studies
  7. ** The denominator for the calculations is a single model-based economic evaluation, including 50 studies